Search

Your search keyword '"Favalli, Ennio Giulio"' showing total 404 results
Start Over Author "Favalli, Ennio Giulio"
404 results on '"Favalli, Ennio Giulio"'

4. Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era.

Author

Luppino, Angela Flavia, Cincinelli, Gilberto, Orenti, Annalisa, Boracchi, Patrizia, Favalli, Ennio Giulio, Caporali, Roberto, and Ingegnoli, Francesca

Subjects
MEDICAL care, COVID-19 pandemic, QUANTILE regression, RHEUMATOID arthritis, SYNTHETIC drugs, DISEASE remission, RHEUMATOLOGISTS
Abstract

Objectives: To analyze the impact of different patterns of healthcare delivery on remission of rheumatoid arthritis (RA) patients treated with targeted therapies during the first wave (2020) and second/third waves (2021) of the pandemic compared to the pre-pandemic period (2019). Methods: In this observational real-life study, data from RA patients treated with biologic or targeted synthetic drugs were extracted from a longitudinal registry. Clinical Disease Activity Index (CDAI) was analyzed in the same period from the 22nd of February to the 18th of May for three consecutive years. These three periods were characterized by different patterns of healthcare delivery: (1) before the pandemic (2019) only in-person visits, (2) during the first wave (2020) both in-person visits and telehealth, and (3) during the second/third waves (2021) only in-person visits. A generalized linear model with the binomial error was fitted to evaluate the difference in the proportion of patients in CDAI remission. Quantile regression was used to compare the median of CDAI in difficult-to-treat (D2T) patients. Results: In the three periods, we included 407, 450, and 540 RA patients respectively. The percentages of patients in CDAI remission were similar in the three periods (prevalence ratio 1.07, p value 0.423 between 2020 and 2019, and 1.01, p-value 0.934 between 2021 and 2019). The CDAI remission rate was 40.55% (N = 163), 43.18% (N = 155) and 40.82% (N = 220) in 2019, 2020 and 2021, respectively. Among our cohort of D2T patients, CDAI remission was similar across the three periods (N = 30, 22.22%; N = 27, 23.68%; and N = 34, 21.52% respectively). Conclusion: Although the pandemic has imposed changes in our healthcare delivery, these different strategies seem to be effective in ensuring satisfactory management of RA treated with targeted therapies. The approaches modulated in the context of the different periods have been a feasible compensation for ensuring disease control even in D2T patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry.

Author

Manfredi, Andreina, Fornaro, Marco, Bazzani, Chiara, Perniola, Simone, Cauli, Alberto, Rai, Alessandra, Favalli, Ennio Giulio, Bugatti, Serena, Rossini, Maurizio, Foti, Rosario, Conti, Fabrizio, Lopalco, Giuseppe, Scalvini, Anna, Garufi, Cristina, Congia, Mattia, Gorla, Roberto, Gremese, Elisa, Atzeni, Fabiola, Caporali, Roberto, and Iannone, Florenzo

Published
2024
Full Text
View/download PDF

12. The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events

Author

Favalli, Ennio Giulio, primary, Cincinelli, Gilberto, additional, Germinario, Sabino, additional, Di Taranto, Raffaele, additional, Orsini, Francesco, additional, Maioli, Gabriella, additional, Biggioggero, Martina, additional, Ferrito, Matteo, additional, and Caporali, Roberto, additional

Published
2023
Full Text
View/download PDF

14. Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium”

Author

Perniola, Simone, primary, Chimenti, Maria Sole, additional, Spinelli, Francesca Romana, additional, Frediani, Bruno, additional, Foti, Rosario, additional, Ferrigno, Sara, additional, Garufi, Cristina, additional, Cassone, Giulia, additional, Venerito, Vincenzo, additional, Atzeni, Fabiola, additional, Caporali, Roberto, additional, Conti, Fabrizio, additional, Favalli, Ennio Giulio, additional, Iannone, Florenzo, additional, Sebastiani, Marco, additional, Ferraccioli, Gian Franco, additional, Lapadula, Giovanni, additional, and Gremese, Elisa, additional

Published
2023
Full Text
View/download PDF

15. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

Author

Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Rusman, Tamara, Østergaard, Mikkel, Hetland, Merete Lund, Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Rusman, Tamara, Østergaard, Mikkel, and Hetland, Merete Lund

Abstract

Objective To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA). Methods Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions: ≤ 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; ≤ 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment. Results Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/ 6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi. Conclusion Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi., OBJECTIVE: To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA).METHODS: Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions: ≤ 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; ≤ 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment.RESULTS: Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/ 6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi.CONCLUSION: Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi.

Published
2023

16. The impact of EMA recommendations on the reallife use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events.

Author

Favalli, Ennio Giulio, Cincinelli, Gilberto, Germinario, Sabino, Di Taranto, Raffaele, Orsini, Francesco, Maioli, Gabriella, Biggioggero, Martina, Ferrito, Matteo, and Caporali, Roberto

Subjects
DISEASE risk factors, JANUS kinases, ABATACEPT, RHEUMATOID arthritis, MAJOR adverse cardiovascular events, CARDIOVASCULAR diseases risk factors
Abstract

Objective: To evaluate in patients with rheumatoid arthritis (RA) the impact of EMA recommendations on the real-life prescription of JAK inhibitors (JAKis) and the use of the Expanded Risk Score in RA (ERS-RA) to quantify the risk of major adverse cardiac events (MACE). Methods: We conducted a retrospective analysis of real-life RA patients treated with JAKis. Patients were classified as ineligible for JAKis if they fulfilled EMA criteria (>65 years-old, history of malignancy, or increased risk of venous thromboembolic events [VTE] or MACE including smoking). Risk of MACE was defined according to ORAL Surveillance trial inclusion criteria (ORALSURV) or by using the ERS-RA. Results: Of 194 patients enrolled, 57.9% were classified as ineligible according to EMA definition (ORALSURV criteria). The most frequent reason for ineligibility was increased MACE risk (70.2%), followed by age>65 (34.2%), smoking (30.7%), and increased risk of VTE (20.2%) or malignancy (7%). The use of the ERS-RA reduced the rate of patients carrying an increased CV risk to 18.6% (p<0.001 versus ORALSURV), leading to 46.4% overall ineligible patients. Over a drug-exposure of 337 patient/years, we observed 2 VTE, one MACE (non-fatal stroke), and one solid malignancy (all in the group of patients classified as ineligible according to both the definitions). Conclusions: Rigorous application of EMA indications in clinical practice could result in the exclusion of a large proportion of RA patients from treatment with JAKis. A proper quantification of the risk for MACE by dedicated tools as ERS-RA is advocated to better tailor the management of RA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”

Author

Vitale, Antonio, primary, Alivernini, Stefano, additional, Caporali, Roberto, additional, Cassone, Giulia, additional, Bruno, Dario, additional, Cantarini, Luca, additional, Lopalco, Giuseppe, additional, Rossini, Maurizio, additional, Atzeni, Fabiola, additional, Favalli, Ennio Giulio, additional, Conti, Fabrizio, additional, Gremese, Elisa, additional, Iannone, Florenzo, additional, Ferraccioli, Gian Franco, additional, Lapadula, Giovanni, additional, and Sebastiani, Marco, additional

Published
2023
Full Text
View/download PDF

19. Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium”

Author

Salaffi, Fausto, primary, Siragusano, Cesare, additional, Alciati, Alessandra, additional, Cassone, Giulia, additional, D’Angelo, Salvatore, additional, Guiducci, Serena, additional, Favalli, Ennio Giulio, additional, Conti, Fabrizio, additional, Gremese, Elisa, additional, Iannone, Florenzo, additional, Caporali, Roberto, additional, Sebastiani, Marco, additional, Ferraccioli, Gian Franco, additional, Lapadula, Giovanni, additional, and Atzeni, Fabiola, additional

Published
2022
Full Text
View/download PDF

20. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

Author

Ørnbjerg, Lykke Midtbøll, primary, Rugbjerg, Kathrine, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon Horskjær, additional, Lindström, Ulf, additional, Pavelka, Karel, additional, Yilmaz, Neslihan, additional, Favalli, Ennio Giulio, additional, Nissen, Michael J., additional, Michelsen, Brigitte, additional, Vieira-Sousa, Elsa, additional, Jones, Gareth T., additional, Ionescu, Ruxandra, additional, Relas, Heikki, additional, Sanchez-Piedra, Carlos, additional, Tomšič, Matija, additional, Geirsson, Arni Jon, additional, van der Horst-Bruinsma, Irene, additional, Askling, Johan, additional, Loft, Anne Gitte, additional, Nekvindova, Lucie, additional, Direskeneli, Haner, additional, Iannone, Florenzo, additional, Ciurea, Adrian, additional, Fagerli, Karen Minde, additional, Santos, Maria José, additional, Macfarlane, Gary J., additional, Codreanu, Catalin, additional, Eklund, Kari, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, Rusman, Tamara, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional

Published
2022
Full Text
View/download PDF

21. AB0454 Safety of Filgotinib in patients with RA: laboratory analysis results from a longterm extension study

Author

Favalli, Ennio Giulio, Buch, Maya H., Galloway, James, Constantin, Arnaud, Durez, Patrick, Van Hoek, Paul, Watson, Chris, Stiers, Pieter-Jan, Rajendran, Vijay, Van Beneden, Katrien, Takeuchi, Tsutomu, Combe, Bernard, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, and UCL - (SLuc) Service de rhumatologie

Subjects
Rheumatology, General Biochemistry, Immunology, Immunology and Allergy, Genetics and Molecular Biology
Abstract

BACKGROUND: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor, approved for treatment of moderate to severe active RA in Europe, the UK, and Japan. Graded laboratory abnormalities from placebo-controlled analyses and long-term data on lymphocytes have been reported previously. OBJECTIVES: Report the effect of FIL on laboratory parameters in the FINCH 4 long-term extension (LTE). […]

Published
2023

24. One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

Author

Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, et al, and University of Zurich

Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health
Published
2022

25. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

Author

Sebastiani, Marco, Anelli, Maria Grazia, Atzeni, Fabiola, Bazzani, Chiara, Farina, Ilaria, Fedele, Anna Laura, Favalli, Ennio Giulio, Fineschi, Irene, Cino, Nicolò, Dal Forno, Ilaria, Gasparini, Stefania, Cassarà, Emanuele, Giardina, Rita, Bruschi, Eleonora, Addimanda, Olga, Cassone, Giulia, Lopriore, Simona, Sarzi-Puttini, Piercarlo, Filippini, Matteo, Pignatti, Federica, Gremese, Elisa, Biggioggero, Martina, Manganelli, Stefania, Amato, Giorgio, Caimmi, Cristian, Salaffi, Fausto, Iannone, Florenzo, Ferri, Clodoveo, Sandri, Gilda, Lapadula, Giovanni, Gorla, Roberto, Govoni, Marcello, Ferraccioli, Gianfranco, Marchesoni, Antonio, Galeazzi, Mauro, Foti, Rosario, Carletto, Antonio, Cantini, Fabrizio, Triolo, Giovanni, Epis, Oscar Massimiliano, and Salvarani, Carlo

Published
2014
Full Text
View/download PDF

26. Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium

Author

Ceccarelli, Fulvia, primary, Govoni, Marcello, additional, Piga, Matteo, additional, Cassone, Giulia, additional, Cantatore, Francesco Paolo, additional, Olivieri, Giulio, additional, Cauli, Alberto, additional, Favalli, Ennio Giulio, additional, Atzeni, Fabiola, additional, Gremese, Elisa, additional, Iannone, Florenzo, additional, Caporali, Roberto, additional, Sebastiani, Marco, additional, Ferraccioli, Gian Franco, additional, Lapadula, Giovanni, additional, and Conti, Fabrizio, additional

Published
2022
Full Text
View/download PDF

29. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability

Author

Iannone, Florenzo, Sinigaglia, Lugi, Favalli, Ennio Giulio, Sarzi-Puttini, Piercarlo, Atzeni, Fabiola, Caporali, Roberto, Codullo, Veronica, Ferraccioli, Gianfranco, Gremese, Elisa, Carletto, Antonio, Giollo, Alessandro, Govoni, Marcello, Bergossi, Francesca, Galeazzi, Mauro, Cantarini, Luca, Salaffi, Fausto, Di Carlo, Marco, Bazzani, Chiara, Pellerito, Raffaele, Sebastiani, Marco, Ramonda, Roberta, and Lapadula, Giovanni

Published
2016
Full Text
View/download PDF

31. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations

Author

Favalli, Andrea, primary, Favalli, Ennio Giulio, additional, Gobbini, Andrea, additional, Zagato, Elena, additional, Bombaci, Mauro, additional, Maioli, Gabriella, additional, Pesce, Elisa, additional, Donnici, Lorena, additional, Gruarin, Paola, additional, Biggioggero, Martina, additional, Curti, Serena, additional, Manganaro, Lara, additional, Marchisio, Edoardo, additional, Bevilacqua, Valeria, additional, Martinovic, Martina, additional, Fabbris, Tanya, additional, Sarnicola, Maria Lucia, additional, Crosti, Mariacristina, additional, Marongiu, Laura, additional, Granucci, Francesca, additional, Notarbartolo, Samuele, additional, Bandera, Alessandra, additional, Gori, Andrea, additional, De Francesco, Raffaele, additional, Abrignani, Sergio, additional, Caporali, Roberto, additional, and Grifantini, Renata, additional

Published
2022
Full Text
View/download PDF

32. Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis

Author

Bugatti, Serena, primary, De Stefano, Ludovico, additional, D’Onofrio, Bernardo, additional, Nicrosini, Andrea, additional, Mauric, Eleonora, additional, di Lernia, Michele, additional, Sakellariou, Garifallia, additional, Favalli, Ennio Giulio, additional, Manzo, Antonio, additional, Caporali, Roberto, additional, and Montecucco, Carlomaurizio, additional

Published
2022
Full Text
View/download PDF

33. Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

Author

Favalli, Ennio Giulio, primary, Gobbini, Andrea, additional, Bombaci, Mauro, additional, Maioli, Gabriella, additional, Biggioggero, Martina, additional, Pesce, Elisa, additional, Favalli, Andrea, additional, Martinovic, Martina, additional, Fabbris, Tanya, additional, Marchisio, Edoardo, additional, Bandera, Alessandra, additional, Gori, Andrea, additional, Abrignani, Sergio, additional, Grifantini, Renata, additional, and Caporali, Roberto, additional

Published
2022
Full Text
View/download PDF

34. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

Author

Favalli, Ennio Giulio, primary, Gobbini, Andrea, additional, Bombaci, Mauro, additional, Maioli, Gabriella, additional, Biggioggero, Martina, additional, Pesce, Elisa, additional, Favalli, Andrea, additional, Martinovic, Martina, additional, Fabbris, Tanya, additional, Marchisio, Edoardo, additional, Bandera, Alessandra, additional, Gori, Andrea, additional, Abrignani, Sergio, additional, Grifantini, Renata, additional, and Caporali, Roberto, additional

Published
2022
Full Text
View/download PDF

35. Additional file 1 of Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine

Author

Spinelli, Francesca Romana, Favalli, Ennio Giulio, Garufi, Cristina, Cornalba, Martina, Colafrancesco, Serena, Conti, Fabrizio, and Caporali, Roberto

Abstract

Additional file 1: Figure S1. Flow-chart of the phone call interview. Figure S2. Multivariable logistic regression analysis showing age- and sex-adjusted risk of systemic adverse events after I and II dose of vaccination in patients and controls. Figure S3. Occurrence of adverse events following immunization according to age and sex in patients and controls. Figure S4. Risk of adverse events following immunization in RMD patients according to ongoing treatment, previous SARS-CoV2 infection and treatment withdrawal prior to vaccination.

Published
2022
Full Text
View/download PDF

37. An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study

Author

Zabotti, Alen, primary, Luchetti, Michele Maria, additional, Selmi, Carlo Francesco, additional, Ramonda, Roberta, additional, Grembiale, Rosa Daniela, additional, Dagna, Lorenzo, additional, D'Angelo, Salvatore, additional, Cafaro, Giacomo, additional, De Vita, Salvatore, additional, Felicetti, Mara, additional, Marelli, Silvia, additional, Frigerio, Daniela, additional, and Favalli, Ennio Giulio, additional

Published
2021
Full Text
View/download PDF

40. Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study

Author

Ingegnoli, Francesca, primary, Ubiali, Tania, additional, Schioppo, Tommaso, additional, Longo, Valentina, additional, Murgo, Antonella, additional, Lucia, Orazio De, additional, Favalli, Ennio Giulio, additional, Iodice, Simona, additional, Bollati, Valentina, additional, and Caporali, Roberto, additional

Published
2021
Full Text
View/download PDF

44. Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection

Author

Batticciotto, Alberto, primary, Marotto, Daniela, additional, Giorgi, Valeria, additional, Balzarini, Patrizia, additional, Favalli, Ennio Giulio, additional, Balduzzi, Silvia, additional, Fredi, Micaela, additional, Bazzani, Chiara, additional, Sartorelli, Silvia, additional, Ravagnani, Viviana, additional, Tamanini, Silvia, additional, Castelnovo, Laura, additional, Lurati, Alfredo Maria, additional, Farah, Sonia, additional, Bongiovanni, Sara, additional, Caporali, Roberto, additional, Dagna, Lorenzo, additional, Faggioli, Paola, additional, Franceschini, Franco, additional, Montecucco, Carlo Maurizio, additional, Salaffi, Fausto, additional, Galli, Massimo, additional, Cappelli, Antonella, additional, and Sarzi-Puttini, Piercarlo, additional

Published
2021
Full Text
View/download PDF

48. Additional file 1 of Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Author

Favalli, Ennio Giulio, Bugatti, Serena, Klersy, Catherine, Biggioggero, Martina, Rossi, Silvia, Lucia, Orazio De, Bobbio-Pallavicini, Francesca, Murgo, Antonella, Balduzzi, Silvia, Caporali, Roberto, and Carlomaurizio Montecucco

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2020
Full Text
View/download PDF

49. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Kvien, Tore K, Balsa, Alejandro, Betteridge, Neil, Buch, Maya H, Durez, Patrick, Favalli, Ennio Giulio, Favier, Guillaume, Gabay, Cem, Geenen, Rinie, Gouni-Berthold, Ioanna, van den Hoogen, Frank, Kent, Alison, Klareskog, Lars, Ostergaard, Mikkel, Pavelka, Karel, Polido Pereira, Joaquim, Semb, Anne Grete, Sköld, Magnus, Dougados, Maxime, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Kvien, Tore K, Balsa, Alejandro, Betteridge, Neil, Buch, Maya H, Durez, Patrick, Favalli, Ennio Giulio, Favier, Guillaume, Gabay, Cem, Geenen, Rinie, Gouni-Berthold, Ioanna, van den Hoogen, Frank, Kent, Alison, Klareskog, Lars, Ostergaard, Mikkel, Pavelka, Karel, Polido Pereira, Joaquim, Semb, Anne Grete, Sköld, Magnus, and Dougados, Maxime

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder with a global prevalence of approximately 0.5-1%. Patients with RA are at an increased risk of developing comorbidities (eg, cardiovascular disease, pulmonary disease, diabetes and depression). Despite this, there are limited recommendations for the management and implementation of associated comorbidities. This study aimed to identify good practice interventions in the care of RA and associated comorbidities. METHODS: A combination of primary research (180+ interviews with specialists across 12 European rheumatology centres) and secondary research (literature review of existing publications and guidelines/recommendations) were used to identify challenges in management and corresponding good practice interventions. Findings were prioritised and reviewed by a group of 18 rheumatology experts including rheumatologists, comorbidity experts, a patient representative and a highly specialised nurse. RESULTS: Challenges throughout the patient pathway (including delays in diagnosis and referral, shortage of rheumatologists, limited awareness of primary care professionals) and 18 good practice interventions were identified in the study. The expert group segmented and prioritised interventions according to three distinct stages of the disease: (1) suspected RA, (2) recent diagnosis of RA and (3) established RA. Examples of good practice interventions included enabling self-management (self-monitoring and disease management support, for example, lifestyle adaptations); early arthritis clinic; rapid access to care (online referral, triage, ultrasound-guided diagnosis); dedicated comorbidity specialists; enhanced communication with primary care (hotline, education sessions); and integrating patient registries into daily clinical practice. CONCLUSION: Learning from implementation of good practice interventions in centres across Europe provides an opportunity to more widely improved care for patient

Published
2020

50. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities

Author

Kvien, Tore K, Balsa, Alejandro, Betteridge, Neil, Buch, Maya H, Durez, Patrick, Favalli, Ennio Giulio, Favier, Guillaume, Gabay, Cem, Geenen, Rinie, Gouni-Berthold, Ioanna, van den Hoogen, Frank, Kent, Alison, Klareskog, Lars, Ostergaard, Mikkel, Pavelka, Karel, Polido Pereira, Joaquim, Semb, Anne Grete, Sköld, Magnus, Dougados, Maxime, Kvien, Tore K, Balsa, Alejandro, Betteridge, Neil, Buch, Maya H, Durez, Patrick, Favalli, Ennio Giulio, Favier, Guillaume, Gabay, Cem, Geenen, Rinie, Gouni-Berthold, Ioanna, van den Hoogen, Frank, Kent, Alison, Klareskog, Lars, Ostergaard, Mikkel, Pavelka, Karel, Polido Pereira, Joaquim, Semb, Anne Grete, Sköld, Magnus, and Dougados, Maxime

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder with a global prevalence of approximately 0.5-1%. Patients with RA are at an increased risk of developing comorbidities (eg, cardiovascular disease, pulmonary disease, diabetes and depression). Despite this, there are limited recommendations for the management and implementation of associated comorbidities. This study aimed to identify good practice interventions in the care of RA and associated comorbidities.METHODS: A combination of primary research (180+ interviews with specialists across 12 European rheumatology centres) and secondary research (literature review of existing publications and guidelines/recommendations) were used to identify challenges in management and corresponding good practice interventions. Findings were prioritised and reviewed by a group of 18 rheumatology experts including rheumatologists, comorbidity experts, a patient representative and a highly specialised nurse.RESULTS: Challenges throughout the patient pathway (including delays in diagnosis and referral, shortage of rheumatologists, limited awareness of primary care professionals) and 18 good practice interventions were identified in the study. The expert group segmented and prioritised interventions according to three distinct stages of the disease: (1) suspected RA, (2) recent diagnosis of RA and (3) established RA. Examples of good practice interventions included enabling self-management (self-monitoring and disease management support, for example, lifestyle adaptations); early arthritis clinic; rapid access to care (online referral, triage, ultrasound-guided diagnosis); dedicated comorbidity specialists; enhanced communication with primary care (hotline, education sessions); and integrating patient registries into daily clinical practice.CONCLUSION: Learning from implementation of good practice interventions in centres across Europe provides an opportunity to more widely impr

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results